Daphne Branham  branham@wustl.edu

Profile picture

phone: (314) 454-2341

Education

  • BS, Massachusetts Institute of Technology2008
  • MD, New York Medical College2015

Training

  • Residency in Pediatrics, Washington University in St. Louis/St. Louis Children's Hospital2015 - 2018
  • Fellowship in Pediatric Emergency Medicine, Medical College of Wisconsin2018 - 2021

Licensure and Board Certification

  • 2015 - PresBasic Life Support
  • 2015 - PresPediatric Advanced Life Support
  • 2018 - 2021WI, Medical License
  • 2018 - 2021WI, DEA
  • 2018 - 2022Pediatric Fundamental Critical Care Support
  • 2018 - PresAdvanced Trauma Life Support
  • 2018 - PresAmerican Board of Pediatrics
  • 2019 - PresImageSIM POCUS Training Course
  • 2021 - PresMO, Medical License
  • 2021 - PresMO, BNDD
  • 2021 - PresMO, DEA

Honors and Awards

  • Career Development Award, 29th Annual Wisconsin Emergency Medicine Forum2021

Recent Publications view all (10)


  1. Examining perceived cancer risk among patients with neurofibromatosis type 1 J Neurooncol. 2015;122(1):127-133. doi:10.1007/s11060-014-1689-6  PMID:25559686 
  2. Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousness Psychooncology. 2013;22(12):2711-2719. doi:10.1002/pon.3350  PMID: 23873824 
  3. Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma Neurology. 2013;81(1):93-94. doi:10.1212/WNL.0b013e318297eea6  PMCID:PMC3770207  PMID:23685934 
  4. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome Genet Med. 2012;14(12):977-982. doi:10.1038/gim.2012.85  PMCID:PMC3982605  PMID: 22878510 
  5. Prospective high-throughput molecular profiling of human gliomas J Neurooncol. 2012;110(1):89-98. doi:10.1007/s11060-012-0938-9  PMCID:PMC3583376  PMID:22821383 
  6. Targeting the epidermal growth factor pathway as therapy for glioblastoma Current Cancer Therapy Reviews. 2012;7(11):65-66. doi:10.2174/157339411794474146  
  7. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor J Clin Oncol. 2011;30(3):30-33. doi:10.1200/JCO.2011.38.4586  PMID:22162573 
  8. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer Neuro Oncol. 2010;12(11):1193-1199. doi:10.1093/neuonc/noq076  PMCID:PMC3098020  PMID:20627894 
  9. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma Neurology. 2009;73(18):1509-1510. doi:10.1212/WNL.0b013e3181bf9907  PMCID:PMC2779003  PMID: 19884580 
  10. Cediranib – Profile of a novel anti-angiogenic agent in patients with glioblastoma Expert Opin Investig Drugs. 2009;10(18):1549-1557. doi:10.1517/13543780903183528  PMCID:PMC2761074  PMID:19671039 
Last updated: 11/23/2021
© 2022 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130